The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis: A Randomized Trial
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder of unknown cause with no effective treatment. Cough affects up to 80% of patients with IPF, is frequently disabling, and lacks effective therapy. OBJECTIVE: To determine the efficacy of thalidomide in suppressing cough in patients with IPF. DESIGN: 24-week, double-blind, 2-treatment, 2-period crossover trial. (ClinicalTrials.gov registration number: NCT00600028) SETTING: 1 university center. PARTICIPANTS: 98 participants were screened, 24 were randomly assigned, 23 received treatment (78.3% men; mean age, 67.6 years; mean FVC, 70.4% predicted), and 20 completed both treatment periods. MEASUREMENTS: The primary end point was cough-specific quality of life measured by the Cough Quality of Life Questionnaire (CQLQ). Secondary end points were visual analogue scale of cough and the St. George's Respiratory Questionnaire (SGRQ). For all measures, lower scores equaled improved cough or respiratory quality of life. RESULTS: CQLQ scores significantly improved with thalidomide (mean difference vs. placebo, -11.4 [95% CI, -15.7 to -7.0]; P < 0.001). Thalidomide also significantly improved scores on the visual analogue scale of cough (mean difference vs. placebo, -31.2 [CI, -45.2 to -17.2]; P < 0.001). In participants receiving thalidomide, scores from the total SGRQ, SGRQ symptom domain, and SGRQ impact domain improved compared with those of participants receiving placebo. Adverse events were reported in 74% of patients receiving thalidomide and 22% receiving placebo; constipation, dizziness, and malaise were more frequent with thalidomide. LIMITATION: This was a single-center study of short duration and small sample size focused on symptom-specific quality of life. CONCLUSION: Thalidomide improved cough and respiratory quality of life in patients with IPF. A larger trial is warranted to assess these promising results. PRIMARY FUNDING SOURCE: Celgene Corporation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 1×
“Participants with 1 adverse event 5 (22) 17 (77) Participants with a serious adverse event 1 (4) 0 (0) Adverse events requiring dose reduction Constipation 0 2 Bradycardia 0 1 Adverse events requiring drug discontinuation Progressive illness or inability to travel for visits 1 2 GI adverse events Constipation 1 (4) 8…”
BackgroundEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Yorke, J., Jones, P. W., & Swigris, J. J. (2010) · Thorax · doi:10.1136/thx.2010.139121 · Cited by 147 · cited 1×
“When we selected these measures at the start of the trial in 2007, no IPF-specific tools for health-related quality of life or cough existed; however, the IPF-specific SGRQ and the Leicester Cough Questionnaire measuring respiratoryspecific quality of life and cough in IPF have subsequently been developed (32, 33).”
Method
Cited by
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Idiopathic pulmonary fibrosis: pathogenesis and management
Sgalla, G., Iovene, B., Calvello, M., Ori, M., Varone, F., & Richeldi, L. (2018) · Respiratory Research · doi:10.1186/s12931-018-0730-2 · Cited by 573
Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases
Rieder, F., Fiocchi, C., & Rogler, G. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.047 · Cited by 529
Abdulqawi, R., Dockry, R., Holt, K., Layton, G., McCarthy, B. G., Ford, A. P., & Smith, J. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61255-1 · Cited by 487
Metadata
- Authors
- Horton, M. R., Santopietro, V., Mathew, L., Horton, K. M., Polito, A. J., Liu, M. C., Danoff, S. K., & Lechtzin, N.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2012-09-18
- Volume
- 157
- Issue
- 6
- Pages
- 398-406
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1980204384
- Cited by
- 204
- References
- 5
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-157-6-201209180-00003
- The paper
- Horton, M. R., Santopietro, V., Mathew, L., Horton, K. M., Polito, A. J., Liu, M. C., Danoff, S. K., & Lechtzin, N. (2012). Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-157-6-201209180-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.